SERG Technologies secures £1.6M funding

London-based medtech SERG Technologies is hoping to achieve regulatory approval for its NuRO platform, a device that provides early diagnosis and monitoring of Parkinson’s disease, having raised £1.6m to help bring it to market. Mercia, Velocity Partners, Newable, the Imperial College Innovation Fund, a leading Japanese corporation and private investors are all part of the funding round.

SERG Technologies was founded in 2019 by Dr Ravi Vaidyanathan and Dr Sam Wilson, based on their research at Imperial College. Its technology uses acoustic sensors to detect movement and assess the state of the patient’s muscles, providing a more objective way to identify the symptoms and measure the severity. The platform enables remote, patient-specific assessment to help optimise treatment and has already been tested on over 100 patients in clinical trials.

It’s fantastic to see so many promising spinouts from UK universities, particularly in growth areas like medtech and pharmatech. SERG, with its vision to enable people with Parkinson’s and other neurodegenerative diseases and movement disorders to live healthier lives, is a perfect example of ‘tech for good’ and we wish the team every success as they work to launch the system in the UK and US. TechMarketView